Drug firm Dr Reddy's Laboratories announced the launch of generic Paricalcitol injection in the US for treatment associated with chronic kidney disease.
In a filing to BSE today, the company announced the launch of the injection USP in the strengths of two mcg, five mcg and 10 mcg.
The company's product is generic version of AbbVie Inc's Zemplar injections, it added.
"The injection is first Abbreviated New Drug Application (ANDA) product launched in the US after approval from the US Food and Drug Administration," it said in the statement.
"The Zemplar brand and generic had US sales of approximately USD 22.5 million MAT for the most recent 12 months ending July 2016 according to IMS Health," added Dr Reddy's statement.
Disclaimer: No Business Standard Journalist was involved in creation of this content
